Genmab to Acquire ProfoundBio for Enhancing its Oncology Portfolio

Share this


Genmab to Acquire ProfoundBio for Enhancing its Oncology Portfolio


  • Genmab has signed a definitive agreement to acquire ProfoundBio for an aggregate of $1.8B in cash to strengthen its oncology portfolio. The transaction will conclude in H1’24
  • Through the acquisition, Genmab gains global rights to ProfoundBio’s ADC portfolio comprising 3 clinical & various preclinical candidates such as rinatabart sesutecan (Rina-S). Additionally, ProfoundBio's ADC technology will be combined with Genmab's Ab platforms for developing products to treat cancer
  • Rina-S, FRα targeting Topo1 ADC, is under P-II of P-I/II trial to treat ovarian cancer & other solid tumors. It received the US FDA’s FTD in Jan 2024 to treat FRα-expressing high-grade serous or endometrioid Pt-resistant ovarian cancer

Ref: Genmab | Image: Genmab

Related News:- AbbVie and Genmab Receive EC’s Conditional Marketing for Tepkinly (epcoritamab) to Treat Relapsed or Refractory Diffuse Large B-cell Lymphoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions